|Home | About | Journals | Submit | Contact Us | Français|
The KCL037 human embryonic stem cell line was derived from a normal healthy blastocyst donated for research. The ICM was isolated using laser microsurgery and plated on γ-irradiated human foreskin fibroblasts. Both the derivation and cell line propagation were performed in an animal product-free environment and under current Good Manufacturing Practice (cGMP) standards. Pluripotent state and differentiation potential were confirmed by in vitro assays.
We generated KCL037 clinical grade hESC line following protocols established previously (Ilic et al., 2012, Stephenson et al., 2012), and now adapted to cGMP conditions. The expression of the pluripotency markers was tested after freeze/thaw cycle (Fig. 1). Differentiation potential into three germ layers was verified in vitro (Fig. 2).
Molecular karyotyping identified decreased copy number at 2q37.3 (242,930,599–242,948,040) and 3q25.1 (151,368,847–151,542,568). The imbalances identified are considered to be benign copy number variants. The chromosome 3 imbalance was not “called” by software.
Whole-genome single nucleotide polymorphism (SNP) array analysis revealed a 542 kb gain on chromosome 18q23 in KCL037 containing two coding genes, SALL3 and ATP9B (Canham et al., 2015). A smaller duplication (nsv577794) covering the same two genes has been reported previously (Cooper et al., 2011).
The KCL037 line is confirmed by PCR to be negative for Cytomegalovirus (CMV), Human T-Cell Lymphotropic Virus 1 (HTLV1), Human Immunodeficiency Virus 1 (HIV1), Hepatitis C Virus (HepC, HCV), Hepatitis B Virus (HepB, HBV) and Epstein–Barr virus (EBV), also called human herpesvirus 4 (HHV4). The testing has been performed by The Doctors Laboratory London.
We also generated research grade of KCL037 line that is adapted to feeder-free conditions.
We distribute Patient Information Sheet (PIS) and consent form to the in vitro fertilization (IVF) patients if they opted to donate to research embryos that were stored for 5 or 10 years. They mail signed consent back to us and that might be months after the PIS and consent were mailed to them. If in meantime new versions of PIS/consent are implemented, we do not send these to the patients or ask them to re-sign; the whole process is done with the version that was given them initially. The PIS/consent documents (FRO-V.6) were created on Dec. 18, 2008. HFEA Code of Practice that was in effect at the time of document creation: Edition 7 – R.4 (http://www.hfea.gov.uk/2999.html). The donor couple signed the consent on Sep. 22, 2009. HFEA Code of Practice that was in effect at the time of donor signature: Edition 7 – R.4. HFEA Code of Practice Edition 7 – R.4 was in effect: 02 Oct. 2008–30 Sep. 2009.
Embryo culture and laser-assisted dissection of inner cell mass (ICM) were carried out as previously described in details (Ilic et al., 2012, Stephenson et al., 2012). The cellular area containing the ICM was then washed and transferred to plates containing mitotically inactivated human neonatal foreskin fibroblasts (HFF).
ICM plated on mitotically inactivated HFF were cultured as described (Ilic et al., 2012, Stephenson et al., 2012). TE cells were removed mechanically from outgrowth (Ilic et al., 2007, Ilic et al., 2010). hES colonies were expanded and cryopreserved at the third passage.
Straws with the earliest frozen passage (p. 2–3) are thawed and new colonies are counted three days later. These colonies are then expanded up to passage 8, at which point cells were part frozen and part subjected to standard battery of tests (pluripotency markers, in vitro and in vivo differentiation capability, genetics, sterility, mycoplasma).
DNA was extracted from hES cell cultures using a Chemagen DNA extraction robot according to the manufacturer's instructions. Amplification of polymorphic microsatellite markers was carried out as described (Ilic et al., 2012). Allele sizes were recorded to give a unique fingerprint of each cell line.
aCGH was performed as described in detail (Ilic et al., 2012).
SNP array was performed as described in detail (Canham et al., 2015).
HLA-A, − B and -DRB1 typing was performed with a PCR sequence-specific oligonucleotide probe (SSOP; Luminex, Austin, TX, USA) hybridization protocol at the certified Clinical Transplantation Laboratory, Guy's and St. Thomas' NHS Foundation Trust and Serco Plc. (GSTS) Pathology (Guy's Hospital, London, UK) as described (Jacquet et al., 2013).
HLA typing was also performed independently by other group (Canham et al., 2015).
There are no competing financial interests in this study.
This work was supported by the UK Medical Research Council grants G0701172 and G0801061. We thank Dr. Yacoub Khalaf, Director of the Assisted Conception Unit of Guy's and St. Thomas' NHS Foundation Trust and his staff for supporting the research program. We are especially indebted to Prof Peter Braude and patients who donated embryos.